维普期刊资源整合服务平台（V6.5）

223篇 您的检索式：作者名="Lancet"

选中清除导出查看参考文献查看引证文献引用追踪共12页首页上一页第1页下一页末页 /12 跳转

	题名	作者	年代	出处	被引量
1	China’s major health challenge: control of chronic diseases显示文摘	The Lancet	2011	The Lancet . 2011 (9790)2011，，：	2
2	Clinical and biologic activity of the arnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias:a phase I clinical-correlative trial显示文摘	Karp JE Lancet JE Kaufmann SH	2001	Blood2001，97，：	1
3	Zarnestra(R115777) in previously untreated poor-risk AML and MDS:preliminary results of a phase Ⅱ trial显示文摘	Lancet JE Karp JE Gotlib J	2002	Blood2002，100，：	1
4	Quality of life and clinical trials显示文摘	Lancet	1995	Lancet1995，346，：	1
5	Teratogenicity of progestogins given during the first trimester of pregnancy显示文摘	Katz Z Lancet M Scomik J Chemke J	1985	Obstet Gynecol 19851985，，：	1
6	Management of acute myelogenous leukemia in the elderly显示文摘	RathnasabapathyR Lancet JE	2003	Cancer Control2003，10，：	1
7	First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunorubi- cin in a fixed 5:I molar ratio for the treatment of relapsed and re- fractory acute myeloid leukemia显示文摘	Feldman EJ Lancet JE Kolitz JE	2011	J Clin Oncol2011，29，8：	1
8	The state of health research worldwide显示文摘	The Lancet	2008	The Lancet2008，372，9649：	1
9	Phase I study of the heat shock protein 90 inhibitor alvespimycin ( KOS-1022, 17-DMAG) administered intravenously twice weekly to pa- tients with acute myeloid leukemia显示文摘	Lancet JE Gojo I Burton M	2010	Leukemia2010，24，：	1
10	Chinese doctors are under threat显示文摘	The Lancet	2010	2010 (9742)2010，，9742：	1
11	The Mexico Statement:strengthening health systems显示文摘	The Lancet	2004	The Lancet2004，364，9449：	1
12	First-in-man study of CPX-351 : a liposomal carrier containing cytarabine and daunorubicin in a fixed 5 : 1 molar ratio for the treatment of re- lapsed and refractory acute myeloid leukemia显示文摘	FELDMAN EJ LANCET JE KOLITZ JE	2011	J Clin Oncol2011，29，8：	1
13	First tricyclic oximino derivatives as 5-HT3 ligands显示文摘	BAGLIN I DAVEU C LANCET J C	2001	Bioorg Med Chem Lett2001，11，4：	1
14	A phase I clinical-pharma- codynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced a- cute leukemias显示文摘	Lancet JE Duong VH Winton EF	2011	Clin Cancer Res2011，17，5：	1
15	The challenge of the dementias 显示文摘	Writing Committee Lancet conference 1996	1996	The Lancet1996，347，：	1
16	A phase 2 study of the oral farnesyltransferase inhibitor tipifamib in patients with refractory or re- lapsed acute myeloid leukemia显示文摘	Harousseau JL Lancet JE Reiffers J	2007	Blood2007，109，12：	1
17	Chinese doctors are under threat显示文摘	The Lancet	2010	The Lancet2010，376，9742：	1
18	Chinese doctors are under threat显示文摘	The Lancet	2010	The Lancet2010，，9742：	1
19	Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias:a phase Ⅰ clinical-laboratory correlative trial显示文摘	Karp J E Lancet J E Kaufmann S H	2001	Blood2001，97，11：	1
20	Phase 2 Trial of the farnesyltrans- ferase inhibitor tipifamib in previously untreated older adults with AML and baseline presence of a specific 2-gene expression signature ratio 显示文摘	Lancet JE Feldman E Foster M	2012	Blood2012，120，21：	1

返回顶部每页显示：

共12页首页上一页第1页下一页末页 /12 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示